Alembic Pharmaceuticals has informed that it enclosed a press release regarding receipt of US Food & Drug Administration (USFDA) Tentative Approval for Dabigatran Etexilate Capsules, 150 mg.
The above information is a part of company’s filings submitted to BSE.